News

The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to

The option, which was obtained through negotiation with the Harvard University’s Office of Technology Development, encompasses an issued US patent that covers engineered variants of protective antigen (PA)

According to Michael Beckert, chief medical officer of LifeCycle Pharma, the Phase II clinical program confirmed that LCP-AtorFen was safe and well-tolerated. In addition, the study showed significantly

NKTR-118 was also shown to be safe and generally well-tolerated at doses up to 250mg twice daily, with no serious or severe adverse events. The pharmacokinetics of NKTR-118

The results demonstrated that mice treated with a soluble form of the ActRIIA receptor increases trabecular bone volume by 45%, 120%, 130% and 248% compared to untreated animals

Pursuant to the settlement and release agreement among Alphatec and DePuy & Biedermann, Alphatec has obtained a license to intellectual property rights owned by Biedermann and licensed to

Cadence’s confirmatory Phase III clinical trial of Omigard (omiganan pentahydrochloride 1% gel), known as the Central Line Infection Reduction Study (CLIRS), is a randomized, evaluator-blinded study in hospitalized

This 24-month, open-label, active-controlled, comparative international study, was the largest since the 1979 Hogarty study to compare the relapse rates of a long-acting injectable antipsychotic and an oral

In addition, the FDA has designated Lev’s complete response as a Class 2 resubmission, establishing an October 14, 2008 target action date to complete its review of the